Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pfizer finalizes acquisition of Global Blood Therapeutics 

By Brian Buntz | October 5, 2022

PfizerIn August, Pfizer (NYSE:PFE) announced its plan to acquire Global Blood Therapeutics (GBT) for $68.50 per share, or roughly $5.4 billion.

Today, the company announced that it had finalized the acquisition, giving it access to GBT’s portfolio of drug candidates for sickle cell disease (SCD).

The GBT acquisition also adds Oxbryta (voxelotor), a novel sickle hemoglobin inhibitor, to its portfolio. Oxbryta has won marketing approval in the U.S., the European Union, United Arab Emirates, Oman and Great Britain.

In 2021, Oxbryta generated $194.7 million in sales, representing a 57% year-over-year increase.

GBT won Orphan Drug and Rare Disease designations from FDA for GBT021601 (GBT601) and inclaclumab, respectively.

Pfizer has developed therapies for rare hematologic diseases for three decades.

The company has been on a spending spree of late.

In March, Pfizer wrapped up a $6.7 billion acquisition of Arena Pharmaceuticals. Two months later, Pfizer announced its plans to acquire migraine drug company Biohaven Pharmaceuticals for $11.6 billion.

“With Global Blood Therapeutics’ talent, portfolio, and pipeline now part of Pfizer, we look forward to accelerating innovation and expeditiously bringing multiple potential best-in-class treatments to people living with sickle cell disease,” said Aamir Malik, chief business innovation officer, executive vice president of Pfizer. “In line with our value of equity, Pfizer is committed to addressing the underserved needs of the sickle cell disease community. We are excited about these potential breakthroughs and the opportunity to transform the lives of these patients,” Malik added in a news release.

Pfizer shares fell 1.28% to $43.89 in mid-day trading today.

In related news, Pfizer continues to score regulatory wins for its updated COVID-19 vaccine booster, which it developed jointly with BioNTech (Nasdaq:BNTX). Today, Japan’s health ministry approved the updated bivalent booster, which protects against the BA.4 and BA/5 subvariants.

In September, Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended the same vaccine for approval.


Filed Under: Hematology
Tagged With: Global Blood Therapeutics
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

DNA matrix image
From Novartis to Pfizer: A closer look at novel cell and gene therapy pricing and reimbursement strategies
Sanofi logo
Rilzabrutinib on track for regulatory filing after ITP trial win
GSK logo
After withdrawal, GSK’s Blenrep shows promise in phase 3 DREAMM-7 study
FDA logo
Core trends in 2023 FDA drug approvals: Oncology, neurology and hematology dominate
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE